Jasper Therapeutics, Inc. (JSPR) stock
Close on Nov 11, 2026Market cap $491.13MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $491.13M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 347.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$31.77M
- EPS, diluted
- -$1.59
- Book value per share
- $0.05
- Diluted shares
- 29M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $14.75
- Open
- $15.04
- Day's range
- $13.64 – $15.45
- Volume
- 69,510
- Average volume (20 days)
- 60,843
- 52-week range
- $0.34 – $72.60
- RSI (14 days)
- 51.7
- Volatility (1 year)
- 16082.8%
- Relative volume
- 0.08×
On 1 of our idea list: Most shorted (a warning list)
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | JSPR | S&P 500 | Difference | JSPR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.7% | -2.4% | −11.3 pts | ||
| 3 months | +1552.7% | -1.2% | +1553.8 pts | ||
| Year to date | -73.1% | +12.3% | −85.4 pts | ||
| 1 year | -71.1% | +12.4% | −83.5 pts | ||
| 3 years | -92.9% | +78.8% | −171.7 pts | -58.5% | +21.4% |
| 5 years | -99.4% | +75.2% | −174.6 pts | -64.2% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Jasper Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- Results
- Update
About Jasper Therapeutics
Biological Products, (No Diagnostic Substances)
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops targeted therapies for mast cell driven diseases. Its primary product candidate is briquilimab, a monoclonal antibody engineered to block stem cell factor from binding to the CD117 receptor, thereby depleting mast cells in tissues such as the skin and lungs. The company's development pipeline focuses on treating conditions including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics designs its therapeutic candidates for adult patients who suffer from these chronic inflammatory disorders, particularly individuals whose symptoms remain uncontrolled by standard antihistamines or other existing medical treatments.
Company profile, executives and historyJasper Therapeutics stock: common questions
What is Jasper Therapeutics's stock price?
JSPR closed at $14.76 on Nov 11, 2026, up 0.07% on the day. Over the past 52 weeks it traded between $0.34 and $72.60.
What is Jasper Therapeutics's market cap?
Jasper Therapeutics was worth $491.13M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is JSPR's P/E ratio?
Jasper Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.59), so it has no meaningful P/E ratio.
Does Jasper Therapeutics pay a dividend?
No. Jasper Therapeutics has not paid a cash dividend over the last twelve months.
When does Jasper Therapeutics report earnings next?
Jasper Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has JSPR stock performed over the past year?
Including dividends, JSPR returned -71.1% over the past year, against +12.4% for the S&P 500.
How many JSPR shares are sold short?
7M shares were sold short at the latest FINRA report, 30.82% of the float, or 17.0 days of average trading volume.
Who are Jasper Therapeutics's competitors?
Companies most similar to Jasper Therapeutics by business, industry and size include ZURA, KYMR, IPSC, ESLA, SRRK.
See a number that looks wrong?